News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

InterMune Reports Third Quarter 2012 Financial Results And Business Highlights



11/8/2012 10:16:11 AM

BRISBANE, Calif., Nov. 7, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced results from operations for the third quarter and nine months ended September 30, 2012.

InterMune reported EsbrietĀ® (pirfenidone) net revenue in the third quarter of 2012 of $7.5 million, approximately 91 percent of which was from Germany, which was the first country in which Esbriet was launched in September 2011. Esbriet revenue was $0.1 million in the third quarter of 2011 which reflected less than one month's revenue of Esbriet from Germany. Esbriet is InterMune's product marketed in Europe for adults with mild-to-moderate idiopathic pulmonary fibrosis (IPF), a chronic and ultimately fatal disease of the lungs.

Read at PR Newswire


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES